- Home
- INVE vs IMA Comparison
INVE vs IMA Comparison
Compare INVE & IMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
HOLD
Current Price
$3.20
N/A
Current Price
$6.70
Company Overview
Basic Information| Metric | INVE | IMA |
|---|---|---|
| Founded | 1990 | 2019 |
| Country | | |
| Employees | N/A | N/A |
| Industry | Computer peripheral equipment | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 80.1M | 65.4M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | INVE | IMA |
|---|---|---|
| Price | $3.20 | $6.70 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 2 | 2 |
| Target Price | $5.50 | ★ $16.00 |
| AVG Volume (30 Days) | 33.7K | ★ 41.8K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $11.82 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.86 | $5.70 |
| 52 Week High | $4.07 | $18.00 |
Technical Indicators
Market Signals| Indicator | INVE | IMA |
|---|---|---|
| Relative Strength Index (RSI) | 47.10 | 45.26 |
| Support Level | $3.09 | $6.81 |
| Resistance Level | $3.41 | $7.21 |
| Average True Range (ATR) | 0.17 | 0.39 |
| MACD | -0.01 | -0.07 |
| Stochastic Oscillator | 46.34 | 16.04 |
Price Performance
Historical Comparison INVE
IMA
About INVE Identiv Inc.
Identiv Inc is a security technology company. It secures and manages access to physical places, things, and information. The company has one reportable segment: the IoT Business segment. Geographically, it generates maximum revenue from the Americas and also has a presence in Europe and the Middle East, and Asia-Pacific.
About IMA ImageneBio Inc.
ImageneBio Inc is a clinical-stage biopharmaceutical company that develops differentiated therapies for immunological and inflammatory (I&I) diseases. The company is focused on developing IMG-007, a non-depleting anti-OX40 monoclonal antibody, for the treatment of atopic dermatitis.